By Stephen Nakrosis 
 

Shares of Cara Therapeutics are trading higher in Monday's after-hours market, following an announcement by Cara and Vifor Pharma that the U.S. Food and Drug Administration approved the Korsuva injection to treat pruritus in hemodialysis patients.

The companies said the Korsuva injection is the first and only therapy approved by the FDA to treat pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.

At 5:54 p.m. ET, Cara shares were trading 24.65% higher at $17.80 a share. Volume at the time topped 5.1 million shares.

The company's shares finished the day's regular-trading session with a 4.23% gain, closing at $14.28 each.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

August 23, 2021 18:18 ET (22:18 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Cara Therapeutics Charts.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Cara Therapeutics Charts.